

**ZORAN CULIG****ORIGINAL PUBLICATIONS:**

1. Tarle M, Culig Z, Kokic I: "Unoccupied prolactin binding components of the benign and malignant human prostate in a subclinical and clinical procedure", **Nucl. Med. Biol. - Int J Radiat Appl Instrum** 16 (5):461-467, 1989.
2. Tarle M, Culig Z, Kovacic K, Spaventi S: "Mechanism of prostate cancer dissemination: small cell adenocarcinoma", **Period Biol** 91 (4):411-414, 1989.
3. Tarle M, Frkovic-Solomon G, Culig Z, Kraljic I, Kovacic K: "Bone scans, tumor marker serotest and hormone values during prostate cancer remission, stabilization and progression in patients with untreated and hormonally treated tumors of various differentiation grades", **Period Biol** 95 (4): 383-394, 1993.
4. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G: "The DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction", **Prostate** 22:11-22, 1993.
5. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: "Mutant androgen receptor detected in an advanced stage prostatic carcinoma is activated by adrenal androgens and progesterone", **Mol Endocrinol** 7:1541-1550, 1993.
6. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor", **Cancer Res** 54:5474-5478, 1994.
7. Cronauer MV, Klocker H, Talasz H, Geisen F, Hobisch A, Radmayr C, Böck G, Culig Z, Schirmer M, Reissigl A, Bartsch G, Konwalinka G: "Inhibitory effects of the nucleotide analogue gemcitabine on prostatic carcinoma cells", **Prostate** 28:172-181, 1996.
8. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: "Androgen receptor status of lymph node metastases from prostatic carcinoma", **Prostate** 28:129-135, 1996.
9. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: "Distant metastases from prostatic carcinoma express androgen receptor protein", **Cancer Res** 55:3068-3072, 1995.
10. Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, Hittmair A, Bartsch G, Cato ACB, Klocker H: "Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone", **Cancer Det Prev** 20:68-75, 1996.

11. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB: "Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding", **Int J Cancer** 63:544-550, 1995.
12. Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, Hittmair A, Culig Z, Bartsch G, Klocker H: "Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cells-specific markers", **Prostate** 30:117-129, 1997.
13. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Klocker H: "Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate", **Prostate** 31:223-233, 1997.
14. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H: "Synergistic activation of androgen receptor by androgen and luteinizing hormone releasing hormone in prostatic carcinoma cells", **Prostate** 32:106-114, 1997.
15. Holzfeind P, Merschak P, Rogatsch H, Culig Z, Feichtinger H, Klocker H, Redl B: "Expression of the gene for tear lipocalin/von Ebner's gland protein in human prostate", **FEBS Lett** 395:95-98, 1996.
16. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, Hobisch-Hagen P, Bartsch G, Klocker H, Culig Z: "Metastatic lesions from prostate cancer do not express estrogen and progesterone receptors", **J Pathol** 182:356-361, 1997.
17. Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zeimet AG, Mörtl MG, Widschwendter A, Marth C: "Activity of retinoic acid receptor selectively binding retinoids alone and in combination with interferon in breast cancer cell lines", **Int J Cancer** 71:497-503, 1997.
18. Cronauer MV, Eder IE, Hittmair A, Sierek G, Hobisch A, Culig Z, Thurnher M, Bartsch G, Klocker H: "A reliable system for the culture of human prostatic cells", **In Vitro Cell Develop Biol** 33:742-744, 1997.
19. Radmayr C, Culig Z, Glatzl J, Neuschmid-Kaspar F, Bartsch G, Klocker H: "Androgen receptor point mutations as the underlying molecular defect in 2 patients with androgen insensitivity syndrome", **J Urol** 158:1553-1556, 1997.
20. Radmayr C, Culig Z, Hobisch A, Corvin S, Bartsch G, Klocker H: „Analysis of a mutant androgen receptor offers a treatment modality in a patient with partial androgen insensitivity syndrome“, **Eur Urol** 33:222-226, 1998.
21. Ischia R, Culig Z, Eder U, Bartsch G, Winkler H, Fischer-Colbrie H, Klocker H: „Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line“, **Prostate** S8:80-87 1998.

22. Culig Z, Hittmair A, Hobisch A, Bartsch G, Klocker H, Pai LH, Pastan I: „Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma“, **Prostate** 36:162-167, 1998.
23. Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder IE, Cronauer MVC, Rieser C, Ramoner R, Bartsch G, Klocker H, Konwalinka G: „Interleukin-1-beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells“, **Br J Cancer** 78:1004-1011, 1998.
24. Culig Z, Archibald B-L, Bichler K-H, v. Dalen A, Kißing F, Klapdor R, Klocker H, Lüdtke R, Marrink J, Mössner E, Obst J, Schmid L, Wagner H, Wieser N, Zwirner M: „Longitudinal quality control with tumor marker tests: results of an international proficiency study with prostate-specific antigen“, **Lab Med** 22:354-360, 1998.
25. Verdorfer I, Culig Z, Hobisch A, Bartsch G, Hittmair A, Duba HC, Erdel M: „Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation“, **Int J Oncol** 13:461-464, 1998.
26. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z: „Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor“, **Cancer Res** 58:4640-4645, 1998.
27. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F, Klocker H: „EGF receptor blockade inhibits the action of EGF, IGF-I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines“, **Cancer Res** 59:227-233, 1999.
28. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H: „Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system“, **Br J Cancer** 81:242-251, 1999.
29. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z: „Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells“, **Br J Cancer** 82:39-45, 2000.
30. Ischia R, Hobisch A, Bauer R, Weiss U, Gasser RW, Horninger W, Bartsch G jr., Fuchs D, Bartsch G, Winkler H, Klocker H, Fischer-Colbrie R, Culig Z: „Elevated levels of serum secretoneurin in patients with therapy-resistant carcinoma of the prostate“, **J Urol** 163:1165-1169, 2000.
31. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H: „Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides“, **Cancer Gene Therapy** 7:997-1007, 2000.
32. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G jr., Klocker H, Bartsch G, Culig Z: „Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue“, **J Pathol** 191:239-244, 2000.

33. Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z: „Antagonist/agonist balance of the nonsteroidal anti-androgen bicalutamide in a new prostate cancer model“, **Urol Int** 65:73-79, 2000.
34. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H: „Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models“, **Prostate** 45:124-131, 2000.
35. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z: „Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype“, **Clin Cancer Res** 7:2941-2948, 2001.
36. Rimler A, Culig Z, Levy G, Lupowitz Z, Klocker H, Matzkin H, Bartsch G, Zisapel N: „Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity“, **Prostate** 49:145-154, 2001.
37. Verdorfer I, Hobisch A, Culig Z, Hittmair A, Bartsch G, Erdel M, Duba HC, Utermann G: „Combined study of prostatic carcinoma by classical cytogenetic analysis and comparative genomic hybridization“, **Int J Oncol** 19:1263-1270, 2001.
38. Rimler A, Culig Z, Lupowitz Z, Zisapel N: „Nuclear exclusion of the androgen receptor by melatonin“, **J Steroid Biochem Mol Biol** 81:77-84, 2002.
39. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z: „Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells“, **Clin Cancer Res** 7:2356-2361, 2002.
40. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z: „The transcriptional coactivator CBP is expressed in prostate cancers and enhances androgen- and antiandrogen-induced androgen receptor function“, **Am J Pathol** 162:233-241, 2003.
41. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z: „Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway“, **Am J Pathol** 162:655-663, 2003.
42. Hobisch A, Fiechtl M, Sandahl Sorensen B, Godoy-Tundidor S, Artner-Dvorak E, Ramoner R, Bartsch G, Culig Z: „Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression“, **Prostate** 59:401-408, 2004.
43. Bektic J, Wulich OA, Dobler G, Kofler K, Überall F, Culig Z, Bartsch G, Klocker H: „Identification of genes involved in estrogenic action in the human prostate using microarray analysis“, **Genomics** 83:34-44, 2004.
44. Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z: „Vascular endothelial growth factor autocrine loop is established in

prostate cancer cells generated after prolonged treatment with interleukin-6", **Eur J Cancer** 40:1066-1072, 2004.

45. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Überall F, Bartsch G, Klocker H: „Long-term androgen ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells“, **Prostate** 58:259-268, 2004.

46. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z,\* Hobisch A\*: “The androgen receptor coactivator CBP is up-regulated following androgen withdrawal and highly expressed in advanced prostate cancer”, **J Pathol** 204:159-166, 2004. (\* joint senior authors)

47. Godoy-Tundidor S, Cavarretta ITR, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A, Culig Z: “Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase”, **Prostate** 64:209-216, 2005.

48. Debes J, Comuzzi B, Schmidt LJ, Dehm S, Culig Z, Tindall D: “p300 regulates androgen receptor-independent expression of PSA in prostate cancer cells treated chronically with interleukin-6”, **Cancer Res** 65:5965-5973, 2005.

49. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z: “The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide”, **Prostate** 66:413-420, 2006.

50. Minelli, Bellezza I, Agostin M, Bracarda S, Culig Z: “Mechanism of 2-chloroadenosine toxicity to PC-3 cell line”, **Prostate** 66:1425-1436, 2006.

51. Neuwirt H, Muller H, Cavarretta ITR, Tiefenthaler M, Bartsch G, Konwalinka G, Culig Z: „Akacid-medical-formulation, a novel biocidal oliguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk ½ mitogen-activated protein kinase pathway“, **Int J Oncology** 29:503-512, 2006.

52. Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z: “Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328”, **Prostate** 66:1744-1752, 2006.

53. Vias M, Burt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG: “A role for neurotensin in bicalutamide resistant prostate cancer cells”, **Prostate** 67:190-202, 2007.

54. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Pühr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z: “Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer”, **Am J Pathol** 169:2199-2208, 2006.

55. Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J: “Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP)”, **Prostate** 67:178-189, 2007.

56. Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z: "The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1", **Oncogene** 26:2822-2832, 2007.
57. Koochekpour S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, Grabowski GA, Culig Z, Minokadeh A: "Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP", **J Cell Biochem** 101:631-641, 2007.
58. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z, Tindall DJ: "Androgen deprivation increases p300 expression in prostate cancer cells", **Cancer Res** 67:3422-3420, 2007.
59. Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z: "Increased resistance to TRAIL-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide", **Prostate** 67:1194-1201, 2007.
60. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z: "SOCS-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion", **Endocr Relat Cancer** 14:1007-1019, 2007.
61. Wegiel B, Bjartell A, Culig Z, Persson JL: "Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival", **Int J Cancer** 122:1521-1529, 2008.
62. Tan S-H, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang J, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT: "Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cell", **Cancer Res** 68:236-248, 2008.
63. Minelli A, Bellezza I, Tucci A, Conte C, Bracarda S, Culig Z: "2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances effects on PC3 cells", **Prostate** 68:360-372, 2008.
64. Neuwirt H, Cedeno Arias M, Puhr M, Hobisch A, Culig Z: "Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells", **Prostate** 68:1647-1654, 2008.
65. Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z: "Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor", **Endocr Relat Cancer** 16:155-169, 2009.
66. Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z: "Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells", **Prostate** 69:538-547, 2009.
67. Neuwirt H, Puhr M, Santer FR, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z: "Suppressor of cytokine signaling (SOCS)-

1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases”, **Am J Pathol** 174:1921-1930, 2009.

68. Malinowska K, Cavarretta IT, Susani M, Wrulich OA, Überall F, Kenner L, Culig Z: “Identification of  $\mu$ -crystallin as an androgen-regulated gene in human prostate cancer”, **Prostate** 69:1109-1118, 2009.

69. Puhr M, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z: “Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways”, **Cancer Res** 69:7375-7384, 2009.

70. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z: „Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion“, **Aktuelle Urol** 40:231-234, 2009. (Alken Award presentation).

71. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z, Altaner C: “Adipose tissue-derived mesenchymal stem cells expressing prodrug converting enzyme inhibit prostate tumor growth”, **Mol Ther** 18:223-231, 2010.

72. Santer FR, Malinowska K, Culig Z, Cavarretta IT: “Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion, and maspin expression in human prostate cancer cells”, **Endocr Relat Cancer** 17:241-253, 2010.

73. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z: “SOCS-3 antagonises proliferative and migratory effects of FGF-2 in prostate cancer by inhibition of p44/p42 MAPK signalling”, **Endocr Relat Cancer** 17:525-538, 2010.

74. Tassidis H, Culig Z, Gjørloff Wingren A, Härkönen P: “Role of the protein tyrosine phosphatase SHP-1 in interleukin-6 regulation of prostate cancer cells”, **Prostate** 70:1491-1500, 2010.

75. Bouchal J, Santer FR, Höschele PPS, Tomastikova E, Neuwirt H, Culig Z: “Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer”, **Prostate** 71:431-437, 2011.

76. Horndasch M, Culig Z: “SOCS-3 antagonizes pro-apoptotic effects of TRAIL and resveratrol in prostate cancer cells”, **Prostate** 71:1357-1366, 2011.

77. Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, Reddy M, Puchalski T, Safer K, Prabhakar U, Pantel K, Qi M, Culig Z: “The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study”, **Prostate** 71:1455-1465, 2011.

78. Shariat SF, Chromecki TF, Hoefler J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT: “Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6-dependent and –independent manner”, **J Urol** 186:2107-2114, 2011.

79. Jenny M, Wondrak A, Zvetkova E, Thi Ngoc Tram N, Thi Phi Phi P, Schennach H, Culig Z, Überall F, Fuchs D: "Crinum Latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cells", **Sci Pharm** 79: 323-335, 2011.
80. Santer F, Höschele P, Oh SJ, Erb H, Bouchal J, Cavarretta IT, Parson W, Meyers D, Cole P, Culig Z: "Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines", **Mol Cancer Ther** 10:1644-1655, 2011.
81. Bouraoui Y, Ben Rais N, Culig Z, Oueslati R: "Involvement of IL-1 beta mediated NF-kappa B signalling pathways to downregulate prostate specific antigen and cell proliferation in LNCaP prostate cancer cells", **Cell Biol Int** 36:449-454, 2012..
82. Hoefler J, Schäfer G, Klocker H, Erb H, Mills IG, Hengst L, Puhr M\*, Culig Z\*: „PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21“, **Am J Pathol** 180:2097-2107, 2012.
83. Oh SJ, Erb H, Hobisch A, Santer F\*, Culig Z: „Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways“, **Endocr Relat Cancer** 19:305-319, 2012.
84. Germann M, Wetterwald A, Guzmán-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED, Thalmann GN: "Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer", **Stem Cells** 30:1076-1086, 2012.
85. Puhr M, Hoefler J, Schäfer G, Erb H, Oh S, Klocker H, Heidegger IM, Neuwirt H, Culig Z: „Epithelial to mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205“, **Am J Pathol** 181:2188-2201, 2012.
86. Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schäfer G, Hall G, Sasser K, Culig Z\*, Santer FR\*: „IL6 sensitizes prostate cancer to the antiproliferative effect of interferon alpha 2 through IRF9“, **Endocr Relat Cancer** 20:677-689, 2013.
87. Hoefler J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z\*, Puhr M\*: „SOCS2 correlates with malignancy and exerts growth promoting effects in prostate cancer“, **Endocr Relat Cancer** 21:175-187, 2014.
88. Puhr M, Hoefler J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z: "PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells", **Oncotarget** 5:12043-12056, 2014.
89. Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, Puhr M, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G: "Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo", **PLoS One** 10:e0117806, 2015.



90. Santer FR, Erb H, Oh S, Handle F, Feiersinger G, Luef B, Bu H, Schäfer G, Ploner C, Egger M, Rane J, Maitland N, Klocker H, Eder IE, Culig Z: “Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy”, **Oncotarget** 6:6105-6122, 2015.
91. Pichler R, Borena W, Schäfer G, Manzl C, Culig Z, List S, Neururer S, von Laer D, Heidegger I, Klocker H, Horninger W, Steiner H, Brunner A: “Low prevalence of HPV detection and genotyping in non-muscle invasive bladder cancer using single-step PCR followed by reverse line blot”, **World J Urol** 33:2145-2151, 2015.
92. Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, Pühr M, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T: “ZEB 1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat”, **EMBO Mol Med** 7:831-847, 2015.
93. Pencik J, Schleder M, Gruber W, Unger C, Walker S, Chalaris A, Marie I, Hassler M, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer O, Mazal P, Grebien F, Egger G, Poli V, Mikulitsch V, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner S, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L: “STAT3 regulated ARF expression suppresses prostate cancer metastasis”, **Nature Comm** 6:7736, 2015.
94. Pühr M, Hoefler J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland A, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z: “PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer”, **Oncogene**, in press.
95. Heidegger I, Hoefler J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z: “Is eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?”, **Prostate** 75:1904-1909, 2015.
96. Slabakova E, Kharashvili G, Smejova M, Pernicova Z, Suchankova T, Remsik J, Lerch S, Strakova N, Bouchal J, Kral M, Culig Z, Kozubik A, Soucek K: “Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells”, **Oncotarget** 6:36156-36171, 2015.
97. Kroon J, Pühr M, Buijs J, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G: “Glucocorticoid receptor antagonism reverts docetaxel-resistance in human prostate cancer”, **Endocr Relat Cancer** 23:35-45, 2016.
98. Handle F, Erb HH, Luef B, Hoefler J, Dietrich D, Parson W, Kristiansen G, Santer FR\*, Culig Z\*: “SOCS3 modulates the response to enzalutamide and is regulated by CpG methylation in prostate cancer cells”, **Mol Cancer Res**, in press.

**REVIEWS AND EDITORIALS:**

1. Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A, Bartsch G: "Androgen signal transduction and prostatic carcinoma", **World J Urol** 12:99-103, 1994.
2. Klocker H, Culig Z, Hobisch A, Cato ACB, Bartsch G: "Androgen receptor alterations in prostatic carcinoma", **Prostate** 25:266-273, 1994.
3. Klocker H, Neuschmid-Kaspar F, Culig Z, Cato ACB, Hobisch A, Eberle J, Cronauer MV, Hittmair A, Radmayr C, Überreiter S, Glatzl J, Bartsch G: "Androgen receptor alterations in patients with disturbances of male sexual development and in prostatic carcinoma", **Urologia Int** 54:2-5, 1995.
4. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor", **Eur Urol** 27 (suppl 2):45-47, 1995.
5. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, Klocker H: "Activation of the androgen receptor by polypeptide growth factors and cellular regulators", **World J Urol** 13:285-289, 1995.
6. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H: "Regulation of prostatic growth and function by peptide growth factors", **Prostate** 28:392-405, 1996.
7. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Bartsch G, Klocker H: "Androgen receptor gene mutations in prostate cancer: implications for disease progression and therapy", **Drugs & Aging** 10:50-58, 1997.
8. Culig Z, Hobisch A, Hittmair A, Peterziel H, Radmayr C, Bartsch G, Cato ACB, Klocker H: "Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?", **Histol Histopathol** 12:781-786, 1997.
9. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Hobisch-Hagen P, Bartsch G, Klocker H: "Paracrine and autocrine stimulation in prostate cancer", **Cancer J** 10:5-9, 1997.
10. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato ACB, Bartsch G, Klocker H: "Expression, structure and function of androgen receptor in advanced prostatic carcinoma", **Prostate** 35:63-70, 1998.

11. Klocker H, Culig Z, Eder IE, Nessler-Menardi C, Hobisch A, Putz T, Bartsch G, Peterziel H, Cato AC: „Mechanism of androgen receptor activation and possible implications for chemoprevention trials“, **Eur Urol** 35:413-419, 1999.
12. Culig Z: „Androgen receptor coactivators: a new research field in prostate cancer“, **J Mol Biol Biotechnol** 1:17-22, 1999.
13. Klocker H, Culig Z, Bartsch G: „Molecular diagnostics of diseases with androgen receptor mutations“, **J Lab Med** 23:327-333, 1999.
14. Culig Z, Hobisch A, Bartsch G, Klocker H: „Androgen receptor – an update of mechanisms of action in prostate cancer“, **Urol Res** 28:211-219, 2000.
15. Culig Z, Hobisch A, Bartsch G, Klocker H: „Expression and function of androgen receptor in carcinoma of the prostate“, **Microscopy Res Techn** 51:447-455, 2000.
16. Smith PC, Hobisch A, Lin D-L, Culig Z, Keller EA: „Interleukin-6 and prostate cancer progression“, **Cytokine Growth Factor Rev** 12:33-40, 2001.
17. Culig Z, Klocker H, Bartsch G, Hobisch A: „Mutations of androgen receptor in carcinoma of the prostate – significance for endocrine therapy“, **Am J Pharmacogenomics** 1:241-249, 2001.
18. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H: „Molecular biology of the androgen receptor: from molecular understanding to the clinic“, **Eur Urol** 40:241-251, 2001.
19. Culig Z, Klocker H, Bartsch G, Hobisch A: „Androgen receptors in prostate cancer“, **Endocr Relat Cancer** 9:155-170, 2002.
20. Culig Z, Bartsch G, Hobisch A: „Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth“, **Mol Cell Endocrinol** 197:231-238, 2002.
21. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A: „Androgen receptors in prostate cancer“, **J Urol** 170:1363-1369, 2003.
22. Culig Z: „Role of androgen receptor axis in prostate cancer“, **Urology** 62 (S1): 21-26, 2003.
23. Klocker H, Eder IE, Culig Z, Bartsch G: „Clinical consequences of androgen receptor malfunction“, **Verh Dtsch Ges Pathol** 88:122-129, 2004.
23. Culig Z: “Androgen receptor cross-talk with cell signalling pathways”, **Growth Factors** 22:179-184, 2004.
24. Culig Z, Bartsch G, Hobisch A: “Antiandrogens in prostate cancer endocrine therapy”, **Curr Cancer Drug Targets** 4:455-461, 2004.
25. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A: „Expression and function of androgen receptor coactivators in prostate cancer“, **J Steroid Biochem Mol Biol** 92:265-271, 2004.

25. Culig Z, Steiner H, Bartsch G, Hobisch A: "Interleukin-6 regulation of prostate cancer cell growth", **J Cell Biochem** 95:497-505, 2005.
26. Culig Z, Steiner H, Bartsch G, Hobisch A: "Mechanisms of endocrine therapy-responsive and –unresponsive prostate tumors", **Endocr Relat Cancer** 12:229-244, 2005.
27. Culig Z, Bartsch G: "Androgen axis in prostate cancer", **J Cell Biochem** 99:373-381, 2006.
28. Minelli A, Bellezza I, Conte C, Culig Z: "Oxidative stress-related aging: a role for prostate cancer?", **Biochim Biophys Acta** 1795:83-91, 2009.
29. Culig Z: „Cytokine disbalance in common human cancers", **Biochim Biophys Acta** 1813:308-14, 2011.
30. Culig Z: "IL-6 causes multiple effects in androgen-sensitive and –insensitive prostate cancer cell lines", **Expert Reviews Endocrinol Metabol** 6:327-332, 2011 .
31. Culig Z, Pühr M: "Interleukin-6: a multifunctional targetable cytokine in human prostate cancer", **Mol Cell Endocrinol** 360:52-58, 2012.
32. Culig Z, Santer FR: "Androgen receptor co-activators in regulation of cellular events in prostate cancer", **World J Urol** 30:297-302, 2012.
33. Culig Z: "Genetic markers in prostate cancer: progress and limitations", **Eur Urol** 62:588-589, 2012.
34. Culig Z: "CXCL8, an underestimated "bad guy" in prostate cancer", **Eur Urol** 64:189-190, 2013.
35. Culig Z: "Interleukin-6 as a therapeutic target in oral squamous cell carcinoma", **Expert Op Ther Targets** 17:53-59, 2013.
36. Culig Z: "Rapidly changing endocrine oncology research: personal reflection of the past, present and future times", **Endocr Relat Cancer** 20:P7-9, 2013.
37. Wu X, Gong S, Roy-Burman P, Lee P, Culig Z: "Current mouse and cell models in prostate cancer research", **Endocr Relat Cancer** 20:R155-170, 2013.
38. Culig Z, Santer F: "Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer", **Steroids**, 78:851-859, 2013.
39. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA: "The mutational landscape of prostate cancer", **Eur Urol** 64:567-576, 2013.
40. Culig Z, Santer FR: "Androgen receptor signaling in prostate cancer", **Cancer Metastasis Rev** 33:413-427, 2014.

41. Culig Z: “Targeting the androgen receptor in prostate cancer”, **Expert Opin Pharmacother** 15:1427-1437, 2014.
42. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, Vecchia CL, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A: “Prevention and early detection of prostate cancer”, **Lancet Oncol** 15:e484-e482, 2014.
43. Culig Z: “Proinflammatory cytokine interleukin-6 in prostate carcinogenesis”, **Am J Clin Exp Urol** 2:231-238, 2014.
44. Perner S, Cronauer MV, Shrader AJ, Klocker H, Culig Z, Baniahmad A: “Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer”, **Oncotarget** 6:35542-35555, 2015.
45. Culig Z: “Androgen receptor coactivators in regulation of growth and differentiation in prostate cancer”, **J Cell Physiol** 231:270-274, 2016.
46. Pencik J, Culig Z, Susani M, Wiebringhaus R, Kenner L: “IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer”, **Swiss Med Weekly** 145:w14215, 2015.